MANGOCEUTICALS, INC. Files 8-K: Material Agreement, Equity Sales
Ticker: MGRX · Form: 8-K · Filed: Jul 23, 2025 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Jul 23, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
TL;DR
MANGOCEUTICALS, INC. filed an 8-K on June 10th for a material agreement and equity sales.
AI Summary
On June 10, 2025, MANGOCEUTICALS, INC. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing was made on July 23, 2025.
Why It Matters
This 8-K filing indicates significant corporate activity for MANGOCEUTICALS, INC., including a new material agreement and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can carry inherent risks related to deal terms and dilution.
Key Numbers
- 001-41615 — SEC File Number (Identifier for MANGOCEUTICALS, INC.'s filings)
- 87-3841292 — IRS Employer Identification No. (Tax identification for MANGOCEUTICALS, INC.)
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- June 10, 2025 (date) — Date of Earliest Event Reported
- July 23, 2025 (date) — Filing Date
- 15110 N. Dallas Parkway , Suite 600 Dallas , Texas 75248 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by MANGOCEUTICALS, INC. on June 10, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales reported by MANGOCEUTICALS, INC.?
The filing mentions unregistered sales of equity securities, but the specific type and amount of securities are not detailed in the provided text.
When was the Form 8-K filed with the SEC?
The Form 8-K was filed as of July 23, 2025.
What is the principal executive office address for MANGOCEUTICALS, INC.?
The principal executive offices are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.
What is the SEC file number for MANGOCEUTICALS, INC.?
The SEC file number for MANGOCEUTICALS, INC. is 001-41615.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 23, 2025 regarding MANGOCEUTICALS, INC. (MGRX).